hLAG3/hPD-1(BALB/cSmoc)

Fig.1 Detection of PD-1 expression on CD4+ T cells and Tregs in spleen of hLAG3/hPD-1(BALB/cSmoc) mice by FACS. Mice were administred Con A (12 mg/kg) by intravenous injection. At 18 h post injection, spleen was collected from the wild-type mouse (male, 7 weeks old) and homozygous hLAG3/hPD-1(BALB/cSmoc) mice (male, 7 weeks old), and analyzed by flow cytometry with anti-mPD-1 and anti-hPD-1. 

Abbr. HO, homozygous; WT, wild type.

Fig.2 In vivo efficacy of Relatlimab plus Nivolumab in hLAG3/hPD-1(BALB/cSmoc) mice. Means of tumor volume(A) and body weight(B). Female, 10-13-week-old homozygous hLAG3/hPD-1(BALB/cSmoc) mice were inoculated subcutaneously in the right flank with CT26 tumor cells (1×10⁶ cells) and grouped when the mean tumor size reaches approximately 100 mm³. Mice received PBS (Group 1), Nivolumab (Group 2, 1 mg/kg) and Relatlimab plus Nivolumab (Group 3, 10 mg/kg Relatlimab and 1 mg/kg Nivolumab) intraperitoneal injection. The tumor volume and body weight were measured twice a week.(n=6, Mean±SEM, t-test, * p < 0.05, ns, no significance).